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Abstract
Objective: To describe factors associated with neurocognitive (NC) function in HIV-positive patients on stable combination
antiretroviral therapy.
Design: We undertook a cross-sectional analysis assessing NC data obtained at baseline in patients entering the Protease-
Inhibitor-Monotherapy-Versus-Ongoing-Triple therapy (PIVOT) trial.
Main outcome measure: NC testing comprised of 5 domains. Raw results were z-transformed using standard and
demographically adjusted normative datasets (ND). Global z-scores (NPZ-5) were derived from averaging the 5 domains and
percentage of subjects with test scores .1 standard deviation (SD) below population means in at least two domains
(abnormal Frascati score) calculated. Patient characteristics associated with NC results were assessed using multivariable
linear regression.
Results: Of the 587 patients in PIVOT, 557 had full NC results and were included. 77% were male, 68% Caucasian and 28% of
Black ethnicity. Mean (SD) baseline and nadir CD4+ lymphocyte counts were 553(217) and 177(117) cells/mL, respectively,
and HIV RNA was,50 copies/mL in all. Median (IQR) NPZ-5 score was20.5 (21.2/20) overall, and20.3 (20.7/0.1) and21.4
(22/20.8) in subjects of Caucasian and Black ethnicity, respectively. Abnormal Frascati scores using the standard-ND were
observed in 51%, 38%, and 81%, respectively, of subjects overall, Caucasian and Black ethnicity (p,0.001), but in 62% and
69% of Caucasian and Black subjects using demographically adjusted-ND (p = 0.20). In the multivariate analysis, only Black
ethnicity was associated with poorer NPZ-5 scores (P,0.001).
Conclusions: In this large group of HIV-infected subjects with viral load suppression, ethnicity but not HIV-disease factors is
closely associated with NC results. The prevalence of abnormal results is highly dependent on control datasets utilised.
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Introduction
Whilst effective combination antiretroviral therapy (cART) has
dramatic effects on the incidence of serious neurological compli-
cations secondary to chronic HIV infection, including severe HIV-
associated dementia [1,2], high rates of more subtle cognitive
decline in HIV infected subjects are being increasingly described
with neurocognitive (NC) impairment rates approaching 50% in
some cohorts [3,4,5]. Several factors have been implicated with
the evolution of NC impairment in the cART era including older
age [3], low nadir CD4+ lymphocyte count [6], chronic hepatitis-
C-virus (HCV) co-infection [7,8] and possibly the use of
antiretroviral regimens with poor central-nervous-system (CNS)
exposure [9].
Given the changing picture of HIV associated CNS disease, a
revised nomenclature system often known as the Frascati criteria,
has been proposed classifying subjects with abnormal NC testing
results into three categories based on patients symptoms measured
via the activities of daily living scale [10]. Subjects with abnormal
NC testing results, who are otherwise asymptomatic are classified
as HIV-associated asymptomatic NC impairment (ANI), who are
mildly symptomatic are classified as HIV-associated mild NC
disorder (MND) and in whom are severely symptomatic classified
as HIV-associated dementia (HAD).
Although high rates of NC impairment in HIV infected subjects
are reported, the clinical characteristics of these reported cohorts
often differ and may include confounding variables which could
influence NC function. For instance antiretroviral treatment status
[11], levels of plasma HIV viraemia and HIV disease stage [12]
and subjects ethnicity [13] vary widely between reports.
In general NC function improves when initiating cART
[14,15,16] and the majority of HIV infected people attending
for care are now on stable ART with full viral load suppression
[17,18]. The aim of this study was to determine the prevalence of
NC impairment and the factors associated with NC function in a
large contemporary cohort of patients on stable ART.
Methods
Subject selection
This cross-sectional analysis included patients whom had agreed
to take part in the Protease Inhibitor monotherapy Versus
Ongoing Triple-therapy in the long term management of HIV
infection (PIVOT) [19] trial. The protocol for this study is
available as supporting information; see Protocol S1. Eligibility
criteria included documented HIV infection; receiving a stable
cART regimen comprising two nucleoside-reverse-transcriptase-
inhibitors (NRTIs) with either a non-nucleoside-reverse-transcriptase-
inhibitor (NNRTI) or a protease-inhibitor (PI) for at least 24 weeks
prior to study entry; a plasma HIV RNA ,50 copies/mL at
screening and for at least 24 weeks prior to screening; and a CD4+
lymphocyte count.100 cells mL. This paper reports the results of the
NC tests done at baseline in patients entering the PIVOT study, prior
to randomisation.
The PIVOT study is registered as ClinicalTrials.gov
NCT01230580. National Research Ethics Service (NRES) ap-
proval for the trial, including the NC assessments, was obtained
from the East of England Cambridge South Ethics Committee.
Neurocognitive measures
NC testing was administered by a designated study nurse or
investigator at each study site who had completed standardised
training to administer the test procedures. Five domains were
assessed as follows; Verbal learning and memory were assessed
using Hopkins Verbal Learning Test-Revised (HVLT-R) for learning
and recall [20], fine motor skills assessed using Grooved Pegboard
[21], and attention and executive function assessed using Colour
Trails Tests (CTT) 1 and 2 [22]. These tests were specifically
chosen to assess the cognitive domains reported to be predomi-
nantly affected in chronic HIV infection [23] and were feasible to
undertake within a multicentre clinical study.
Subjects also self-completed an anxiety and depression score
questionnaire (EQ-5D, [24]) selecting one of the three following
options: 1) I am not anxious or depressed, 2) I am moderately
anxious or depressed, 3) I am extremely anxious or depressed.
Normative standards
Raw scores for each cognitive test were transformed to z-scores
using the manufacturers’ normative data [20,21,22] matched for
each participant by age (for all tests) and also by years of education
(only for the CTT). These reference data were of US origin and in
general derived from a large number of subjects (over 1000) of
predominantly Caucasian ethnicity. Additionally we utilise nor-
mative data considering ethnicity which were available for the
CTT [22] and the HVLT domains [25]: Here, normative data
were provided separately for subjects of Caucasians and Black
(African-American) ethnicity although subject numbers for the
latter group (approximately 150 control subjects) were smaller. In
addition, for HVLT and CTT these alternative normative data
did not distinguish between age groups and years of education,
respectively, and for CTT the age categories for Black ethnicity
did only cover the range of 20 to 50 years.
Statistical analyses
Only subjects in whom full NC testing results were available
from all 5 domains were included in the analyses. Baseline patient
characteristics, and ART and HIV disease histories for all eligible
subjects were tabulated separately for subjects of Caucasian and
Black ethnicity. We calculated the CNS Penetration Effectiveness
(CPE) score based on the 2010 scoring system for study baseline
antiretroviral regimens [26] and calculated each subjects 10 year
cardiovascular risk [27].
For each cognitive domain, z-scores were calculated by
subtracting the mean and dividing by the standard deviation
(SD) of test scores in reference populations using both the standard
and demographically adjusted normative datasets. The z-score for
the fine motor skills domain was obtained by taking the average of
the z-scores for the dominant and non-dominant hands on the
Grooved Pegboard tests. Global z-scores (NPZ-5) were derived
from averaging the 5 domains. For all individual test z scores and
the NPZ-5, scores above zero denote above-average neurocogni-
tive function and scores below zero denote below-average
neurocognitive function compared to the reference population. Z
scores of each individual test were dichotomised based on a
threshold of one SD below the mean of the normative dataset (i.e.
,21).
In addition we used two measures for defining abnormal NC
function. Firstly, the percentage of subjects having a global NPZ-
5,21. Secondly, we calculated the percentage of subjects with
test scores ,21 in at least two individual domains, corresponding
to a previously published definition, frequently known as the
Frascati score [10]. We categorised subjects into having an
‘abnormal Frascati score’ if at least two cognitive domains scored
,21 or otherwise categorised as having a ‘normal Frascati score’.
As no formal activities of daily living scale was assessed, we were
not able to subcategorise subjects in the ANI, MCD and HAD
categories.
The PIVOT Neurocognitive Study
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Prevalence of abnormal NC function using these measures were
calculated using standard and ethnicity adjusted normative data,
for the overall study population, and separately for subjects of
Caucasian and Black ethnicity.
Proportions were compared using chi-square test. Simple
comparisons of test scores were made using Mann-Whitney or
Kruskal-Wallis rank tests. We used univariable and multivariable
linear regression models to identify baseline factors associated with
test scores (NPZ-5, z-scores), investigating gender, age, ethnicity,
years of education, nadir and current CD4+ T-cell count, time
since HIV RNA suppression, years on ART, current use of
NNRTIs, current or past use of efavirenz, CPE score of current
regimen, current and past smoking, cardiovascular (CV) risk,
presence of hepatitis C virus (HCV) antibodies, baseline haemo-
globin, and anxiety/depression level.
Results
Patient characteristics
Full NC results were available for 557 of the 587 subjects
enrolled into PIVOT with baseline characteristics shown in Table 1.
Of interest, and of potential clinical relevance, although current
CD4+ lymphocyte count (mean, SD) was relatively high at 553
(217) cells/mL, nadir CD4+ lymphocyte count was 177 (117) cells/
mL. Subjects had been receiving cART for a mean of 5 (SD 3)
years with 53% of the cohort receiving an NNRTI based regimen
and 39% receiving an efavirenz containing regimen at baseline.
Thirty-one per cent of subjects reported moderate anxiety or
depression with only 2% of subjects reporting extreme anxiety.
The majority of subjects were of Caucasian (68%) or Black
(28%) ethnicity with only 20 subjects (4%) of other ethnicities. In
general, baseline characteristics were similar between these groups
apart from the much higher proportion of men in the Caucasian
group.
Neurocognitive test results utilising standard normative
data
Using the standard normative dataset, median (IQR) NPZ-5
scores was 20.5 (21.2, 20) overall, and 20.3 (20.7, 0.1) and
21.4 (22, 20.8), respectively, in subjects of Caucasian and Black
ethnicity (Table 2). In all ethnic groups, NPZ-5 scores were
significantly below 0 (P,0.001 in all). Overall, 32% of subjects had
a global NPZ-5 score ,21, with a significantly different
prevalence in Caucasian and Black subjects (17% vs. 67%;
P,0.001). When assessing the number of subjects with an
abnormal Frascati score a similar trend was observed, although
proportions of abnormal findings were generally higher, with 51%,
38% and 81%, respectively, of subjects overall, of Caucasian and
of Black ethnicity (P,0.001 for difference between Caucasian and
Black ethnicity).
In 80% of subjects overall, the two definitions of impairment
were in agreement (Figure 1), and NPZ-5 score and the Frascati
criteria were either both ‘normal’ (48%) or both ‘abnormal’ (31%).
In 1% of subjects, NPZ-5 score was,21 but Frascati criteria were
classified as normal, and vice versa in 20%. Hence, discordance
between findings based on NPZ-5 scores and the Frascati criteria
was predominantly due to an abnormal Frascati score definition in
the presence of a NPZ-5 score which was above our cut-off of 1
SD below normative means. Agreement was 77% in Caucasians,
and 85% in patients of Black ethnicity.
Factors associated with global cognitive scores
NPZ-5 scores were not quite normally distributed (slightly
skewed to the left). However, differences between ethnic groups
were very similar using univariable linear regression compared to
the statistics given in Table 2. These differences between ethnic
groups remained nearly unchanged in a multivariable model, that
is after adjustment for demographic and clinical variables and
other potential influence factors of NC performance. Both Black
(21.1 score points; 95% CI 21.3 to 20.9) and other ethnicity
(20.6 score points; 95% CI 21.0 to 20.3) were associated with
poorer NPZ-5 scores compared with Caucasians (overall P value
for ethnic group ,0.001).
Because of an apparent influence of the reference data used (see
below), we decided to assess factors associated with NPZ-5 scores
separately for subjects of Caucasian and Black ethnicity; numbers
for other ethnicity were considered too small for meaningful
multivariable analyses.
In subjects of Caucasian ethnicity, current nevirapine use (0.34
score points less in those on nevirapine; p = 0.021) and HCV (0.33
score points less in those with detectable antibodies; p = 0.047)
were associated with lower NPZ-5 scores (Table 3). Of note, the
association with nevirapine was adjusted for previous cessation of
efavirenz due to CNS toxicity, and results were very similar when
instead adjusting for never, current, previous use of efavirenz (i.e.
ignoring recorded cause of cessation). 20/43 of patients currently
on nevirapine have been on efavirenz before, of which 12 had
stopped efavirenz due to CNS toxicity, however, in patients on
nevirapine adjusted NPZ-5 scores were 20.63 and 20.54,
respectively, in those never and previously on efavirenz. There-
fore, association with nevirapine was unlikely being confounded by
a previous switch from efavirenz.
In subjects of Black ethnicity, smoking was the only factor
associated with NPZ-5 scores: current and ex-smokers had 0.68
and 0.37, respectively, score points higher than subjects who never
smoked (overall p = 0.022) (Table 3).
Other HIV disease factors such as nadir CD4+ lymphocyte
count and antiretroviral factors such as CPE score were not
associated with NPZ-5 score in either ethnic group.
Neurocognitive test results utilising demographically
adjusted normative data
Using the demographically adjusted normative data, the
differences between ethnicities were less marked with poorer
results for subjects of Caucasian ethnicity and better results for
subjects of Black ethnicity compared with using the standard
normative data (Table 2). Although a statistically significant
difference in the number of subjects with NPZ-5 scores,21
remained between ethnicities (P=0.001), the difference was no
longer statistically significant in numbers of subjects meeting the
Frascati criteria (P = 0.20). Of note, whereas there was a significant
difference in NPZ-5 scores between Caucasian and Black subjects
in univariable regression analysis (p,0.001), the difference
disappeared-in contrast to the analysis using the standard
normative dataset-when adjusting for demographic, clinical and
other factors (p = 0.31).
Discussion
We have assessed NC function in a large group of HIV infected
subjects on effective cART using a standard cognitive testing
battery. Although this is not the same as a formal neurophyscho-
logical assessment, the brief neurocognitive test battery we used
comprised validated components of standard formal neuropsy-
chological tests [28] and we have made several interesting and
novel observations relevant to both current clinical practice and
future research in this field.
The PIVOT Neurocognitive Study
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In our study, the median global NPZ-5 score for Caucasian
subjects, using the standard normative control data, was 20.3 and
therefore slightly lower than 0 which to be expected in a normal
population. However, these data are reassuring insofar as the
difference is quite small and unlikely to be functionally significant
[29], suggesting that in effectively treated HIV infected subjects
global cognitive function is similar to normative control data.
Furthermore, the small difference may be driven by factors other
than HIV infection that can influence neurocognitive function
such as differences in rates of smoking that may differ from the
normative dataset. We did not have an HIV-negative comparison
group in our study which might have provided further clarity on
this. Our study differs from other reports where poorer global
NPZ-5 scores in HIV infected cohort are described [5,6]. We
postulate these differences may in part be due to differences in the
populations studied. In our study, all subjects were virologically
suppressed at the time of study and had been so for a mean of 4
years. Previous studies have reported improvements in cognitive
function in HIV infected subjects commencing antiretroviral
therapy with the dynamic of these improvements evident for at
least a one year period [15,30]. Although we did not find evidence
for this in the model, it may be that improvements in cognitive
function may continue for many years until global cognitive scores
in a group of patients may start to match control population
values.
Despite global NPZ-5 scores in Caucasian subjects being similar
to the standard normative control data, high rates of abnormalities
were observed when we assessed results using the Frascati criteria
with 37% of subjects having an abnormal Frascati score in this
group. These results differ from a recent study conducted in the
UK where Garvey et al described only 19% of Caucasian individuals
to have an abnormal Frascati score [31]. In this study, global NPZ
scores were also similar to population control data. The differences
may be due to the patient selection and nature of the testing
performed but it is also possible that these differences could be due
to the normative datasets used in our study compared to the study
conducted by Garvey et al. In our study we undertook traditional
NC testing where the normative control dataset originate from
historic US cohorts, some dating from the 1960s and 1970s. Garvey
et al undertook computerised NC testing (CogStateTM, Mel-
bourne, Australia) where the control population are predominant-
ly Caucasian male Australian subjects recruited within the last
Table 1. Baseline characteristics, overall, and separately for subjects of Caucasian and Black ethnicity.
Variable Overall1 (n = 557) Caucasian ethnicity (n =381) Black ethnicity (n =156)
Gender, male 427 (77) 353 (93) 61 (39)
Age, years 44 (9) 45 (10) 44 (8)
Nadir CD4+, cells/mL 177 (117) 189 (117) 147 (109)
Baseline CD4+, cells/mL 553 (217) 569 (219) 512 (205)
Years undetectable HIV RNA 4 (3) 4 (3) 4 (3)
Years education 15 (4) 15 (4) 15 (4)
Years on cART 5 (3) 5 (3) 5 (3)
on NNRTI 296 (53) 187 (49) 102 (65)
Efavirenz
never on 217 (39) 147 (39) 59 (38)
not currently on but previously 125 (22) 93 (24) 27 (17)
currently on 215 (39) 141 (37) 70 (45)
efavirenz ever stopped due to CNS problems{ 67 (12) 55 (14) 11 (7)
baseline CPE score 7 (1) 7 (1) 8 (1)
Smoker
never 261 (47) 143 (38) 113 (72)
current 157 (28) 135 (35) 17 (11)
ex-smoker 139 (25) 103 (27) 26 (17)
CV risk
,10% 341 (61) 199 (52) 127 (82)
10–20% 187 (34) 158 (41) 26 (17)
.20–30% 28 (5) 24 (6) 2 (1)
Hepatitis C antibody positive 21 (4) 18 (5) 2 (1)
Baseline haemoglobin, g/dL 14 (1) 15 (1) 13 (1)
Anxiety/Depression
not anxious/depressed 369 (67) 249 (66) 106 (70)
moderately anxious/depressed 173 (31) 121 (32) 46 (30)
extremely anxious/depressed 9 (2) 9 (2) 0
Table 1 legend: 1only patients with complete neurocognitive data (including patients of ethnicity other than Caucasian or Black, n = 20); {5/67 (all Caucasian) were back
on efavirenz at baseline; cART = combination antiretroviral therapy, CPE = Clinical Penetration Effectiveness, CV = cardiovascular, NNRTI = non-nucleoside reverse-
transcriptase inhibitor; Data are number (%) or mean (standard deviation).
doi:10.1371/journal.pone.0061949.t001
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decade. With cultural changes over time, it is possible that the
CogStateTM control dataset is more representative of our
Caucasian cohort recruited over the past few years in the UK
and therefore when a NC score is calculated which encompasses
results from several cognitive domains, such as the Frascati score,
such differences in results become apparent.
We observed poorer results within individual NC domain scores
(data not shown), global NPZ-5 scores and the categorical score
using the Frascati criteria in our study for subjects of Black
ethnicity compared to subjects of Caucasian ethnicity. There are
several plausible explanations for these findings. All tests were
undertaken using instructions in English and it is possible language
difficulties could account in part for these differences. However we
do not believe this to be an important factor because the
differences were no more marked on the HVLT tests, which are
highly language-dependent, than they were on the other tests
which do not depend on linguistic fluency. Furthermore, the
majority of the Black patients attending clinics in the UK are
either born in the UK, or are immigrants from African countries
where English is widely spoken, and patients who were not able to
understand the study instructions were not included. Patients who
appeared to understand the instructions but then performed the
Table 2. Neurocognitive testing results.
Parameter Overall1 (n = 557)
Caucasian
ethnicity (n=381)
Black ethnicity
(n=156)
Other ethnicity
(n=20)
P-value for difference
between Caucasian vs.
Black ethnicity
Standard
normative data
NPZ-5 score 20.5 (21.2, 20)
[95%CI 20.8, 20.6]
20.3 (20.7, 0.1)
[95%CI 20.4, 20.3]
21.4 (22, 2.8)
[95%CI 21.8, 21.4]
20.8 (21.3, 20.4)
[95%CI 21.3, 20.6]
,0.001
Overall NPZ-5 score .1 SD
below population mean
179 (32) 66 (17) 104 (67) 9 (45) ,0.001
At least 2 individual
tests with z-score .1 SD
below population mean
285 (51) 144 (38) 127 (81) 14 (70) ,0.001
Adjusted
normative data"
NPZ-5 score 20.8
(21.3, 20.3)
21.1 (21.6, 20.6) ,0.001
Overall NPZ-5 score.1 SD
below population mean
145 (38) 69 (55) 0.001
At least 2 individual tests
with z-score.1 SD below
population mean
236 (62) 86 (68) 0.20
Table 2 legend: 1patients with complete neurocognitive data including patients of ethnicity other than Caucasian or Black (n = 20); IQR = interquartile range, SD =
standard deviation; "Excludes all patients of ethnicity other than Caucasian and Black, as well as 30 subjects of Black ethnicity who fell outside the age range covered by
the adjusted normative data; NPZ-5 results using standard normative data in these 30 patients were similar to those of the other 126 patients. Data are number (%) or
median (interquartile range).
doi:10.1371/journal.pone.0061949.t002
Figure 1. Association between NPZ-5 score and Frascati score.
doi:10.1371/journal.pone.0061949.g001
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tests incorrectly would also have been excluded as the tests would
have been deemed invalid. Differences in HIV disease factors or
other characteristics at baseline could also explain such differences.
However, baseline characteristics were similar for subjects of
Caucasian and Black ethnicity in many areas, and the influence of
ethnicity persisted after adjusting for baseline factors.
We hypothesise the differences in NC test results between the
ethnicities observed in our study are due to differences in the
characteristics of control datasets available for use for several
reasons. Firstly, when utilising the demographically adjusted
normative dataset, the differences between ethnicities become less
marked and indeed no statistically significant difference is
observed in the Frascati criteria definition between Caucasian
and Black ethnicities when we use this adjusted normative data.
Secondly, as described above, for Caucasian subjects, in other
studies using different normative datasets [31,32], quite different
results are observed. Lastly, results of NC testing from control
datasets which are recruited specifically to match HIV infected
cohorts are described to differ substantially from traditional
population control datasets [13]. Indeed the effects of ethnicity
on cognitive function and lack of appropriate control data have
previously been described in a female HIV-infected cohort [13].
A finding from our study which remains challenging is to
explain the poorer NC testing results observed in Caucasian
subjects when using the demographically adjusted dataset com-
pared to the standard normative dataset. Again this may be related
to differences in the Caucasian controls used within these control
datasets however this area requires further investigation.
Nadir CD4+ lymphocyte count has been associated with greater
risk of NC impairment in many reports [6,31,33], a finding we did
Table 3. Linear regression analysis assessing factors associated with NPZ-5 scores.
Univariable Multivariable
Study parameter Caucasian ethnicity Black ethnicity Caucasian ethnicity Black ethnicity
Coef. [95% CI] P Coef. [95% CI] P Coef. [95% CI] P Coef. P
Gender, female vs. male 0.06 [20.19, 0.32] 0.63 20.10 [20.40, 0.21] 0.54 0.03 [20.25,0.32] 0.83 20.05
[20.49,0.40]
0.83
Anxious/depressed at baseline
(moderately or extremely vs. Not)
20.12 [20.26, 0.02] 0.09 20.00 [20.33, 0.32] 0.99 20.11
[20.25,0.04]
0.14 0.04 [20.32,0.40] 0.83
Efavirenz, on at baseline
vs. not on
0.04 [20.09, 0.18] 0.54 20.12 [20.41, 0.18] 0.44 20.05
[20.22,0.11]
0.53 20.25
[20.62,0.12]
0.19
Nevirapine, on at baseline
vs. not on
20.28 [20.49, 20.07] 0.009 20.07 [20.44, 0.31] 0.72 20.34 20.63,
20.05
0.021 20.08
[20.62,0.47]
0.79
Ever stopped efavirenz due
to CNS problems, (yes v. No)
0.07 [20.12, 0.26] 0.49 20.23 [20.80, 0.34] 0.42 0.09 [20.11,0.29] 0.39 20.16
[20.79,0.47]
0.62
Smoker, vs. never
current smoker 0.02 [20.14, 0.18] 0.80 0.63 [0.17, 1.10] 0.008 0.05 [20.13,0.22] 0.60 0.68 [0.11,1.25] 0.020
ex-smoker 0.13 [20.04, 0.30] 0.13 0.30 [20.09, 0.70] 0.13 0.12 [20.05,0.29] 0.17 0.37 [20.08,0.82] 0.11
Cardiovascular risk, .= 10%
vs. ,10%
20.06 [20.20, 0.07] 0.36 20.01 [20.40, 0.38] 0.96 20.05
[20.20,0.10]
0.53 20.32
[20.80,0.15]
0.18
Hepatitis C antibody,
positive vs. negative
20.30 [20.61, 0.01] 0.061 20.44 [21.74, 0.86] 0.51 20.33 [20.65,
20.00]
0.047 20.26
[21.63,1.11]
0.70
Prior AIDS illness, yes vs. no 0.05 [20.13, 0.23] 0.58 20.10 [20.45, 0.25] 0.58 0.02 [20.17,0.22] 0.82 20.12
[20.54,0.30]
0.57
Age, per 10 years 20.05 [20.12, 0.02] 0.14 20.06 [20.25, 0.13] 0.55 20.05
[20.13,0.03]
0.21 20.04
[20.26,0.18]
0.74
CD4+ nadir, per increasing
100 cells/mL
20.03 [20.09, 0.02] 0.26 0.00 [20.13, 0.14] 0.97 20.01
[20.08,0.06]
0.81 20.09
[20.26,0.09]
0.34
CD4+ at baseline, per increasing
100 cells/mL
20.03 [20.06, 0.00] 0.06 20.00 [20.07, 0.07] 0.95 20.02
[20.06,0.01]
0.20 0.01 [20.09,0.11] 0.80
Years with undetectable HIV RNA 20.01 [20.03, 0.01] 0.45 20.04 [20.10, 0.02] 0.19 0.00 [20.03,0.04] 0.90 20.04
[20.13,0.05]
0.34
Years of known HIV infected 20.01 [20.02, 0.01] 0.41 20.00 [20.04, 0.04] 0.995 0.00 [20.01,0.02] 0.60 0.03 [20.03,0.09] 0.34
Years of education 20.08 [20.17, 0.01] 0.10 0.03 [20.16, 0.22] 0.75 20.02
[20.04,0.00]
0.089 0.00 [20.04,0.05] 0.91
Number of different ART
drugs received
20.02 [20.06, 0.02] 0.31 20.12 [20.21, 20.02] 0.021 20.02
[20.07,0.03]
0.53 20.09
[20.22,0.04]
0.17
Haemoglobin, per g/dl 0.01 [20.05, 0.07] 0.80 0.05 [20.06, 0.15] 0.39 0.02 [20.05,0.09] 0.60 20.00
[20.15,0.14]
0.97
CPE score of regimen 20.02 [20.09, 0.05] 0.59 20.00 [20.14, 0.14] 0.99 0.03 [20.06,0.13] 0.50 20.05
[20.24,0.15]
0.62
Table 3 legend: CI = confidence interval; CPE = Clinical Penetration Effectiveness; NPZ-5 =mean neuropsychiatric z-score for 5 domains; Coef= regression coefficient. P
values (P),0.05 shown in bold. "Overall p-value for smoking in subjects of Black ethnicity 0.016 (univariable) and 0.022 (multivariable).
doi:10.1371/journal.pone.0061949.t003
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not observe within our cohort. The longer duration of effective
antiretroviral therapy and a lack of historic documented virolog-
ical failure differs from other studies and is a possible explanation.
We observed an association between current nevirapine use in
Caucasian subjects and poorer NC function which has not been
previously described. This is an unexpected finding as nevirapine is
considered to have pharmacokinetic exposure at effective concen-
trations in the cerebrospinal fluid [34] and no in vitro data to our
knowledge have reported any neuronal toxicities associated with
nevirapine. We believe this may be a channelling bias whereby
subjects with pre-existing NC impairment or psychiatric conditions
are preferentially commenced on nevirapine. In our multivariate
model, ever stopping efavirenz due to CNS toxicities was not
associated with global NPZ-5 scores, which may suggest the
association we have observed with nevirapine is not associated with
subjects switching to nevirapine from other cART regimens with
overt CNS toxicities. However this association does not address the
channelling bias associated with commencing a nevirapine regimen
de novo in subjects previously naive to antiretroviral therapy.
Several findings from our study are highly relevant to this field of
HIV medicine. Of important to clinicians caring for HIV infected
individuals and for HIV community groups, our description of a large
cohort where overall NC function in subjects on cART for many years
is similar to a matched HIV seronegative control population, albeit
only within the Caucasian cohort in whom we believe the matched
population datasets are the most relevant, is reassuring. Although we
are not able to tease out pathogenic mechanisms associated with
cerebral dysfunction, we are able to provide reassuring data that in
general NC function within a well cared for cohort, does not
substantially differ from a control population. Another seminal finding
from our work for future clinical research, is the importance of
recruiting well matched control populations to the HIV infected
populations being studied, in order to aid the interpretation of study
findings and in order to assess if findings are related to HIV-disease
itself or the cohorts being studied.
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